J&J trial links anemia drug to patient deaths in stroke trial

09/18/2008 | Google

Preliminary results of a study on Eprex -- an anemia drug developed by Johnson & Johnson's Ortho Biotech unit and sold as Procrit in the U.S. -- showed that more ischemic stroke patients who received the drug died compared with those who received a placebo, the company announced Wednesday. Ortho Biotech said it has notified U.S. and European regulators and is undertaking further analyses of the results.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ